M P Davis


Affiliation: Cleveland Clinic Foundation
Country: USA


  1. request reprint
    Davis M. What is new in neuropathic pain?. Support Care Cancer. 2007;15:363-72 pubmed
    ..For this reason, SNRIs and gabapentin/pregabalin have become popular though efficacy is not better than TCAs. Multiple drug therapies becoming an emergent treatment paradigm research in multiple drug therapy are needed. ..
  2. Davis M. Sigma-1 receptors and animal studies centered on pain and analgesia. Expert Opin Drug Discov. 2015;10:885-900 pubmed publisher
  3. Davis M, Gamier P. New Options in Constipation Management. Curr Oncol Rep. 2015;17:55 pubmed publisher
    ..This review will discuss the evidence-based benefits of these medications and outline an approach to managing constipation. ..
  4. request reprint
    Davis M, Shaiova L, Angst M. When opioids cause pain. J Clin Oncol. 2007;25:4497-8 pubmed
  5. request reprint
    Davis M, Walsh D. Mechanisms of fatigue. J Support Oncol. 2010;8:164-74 pubmed
    ..This state-of-the-art review discusses these physiologic correlates of fatigue and the mechanisms described in a variety of chronic diseases. ..
  6. Davis M. Fentanyl for breakthrough pain: a systematic review. Expert Rev Neurother. 2011;11:1197-216 pubmed publisher
    ..OTFC and INFS have been used effectively to reduce acute pain in children who are opioid-naive. Abuse and addiction to OTFC, fentanyl buccal tablets and INFS was low, owing to patient selection. ..
  7. Davis M, Strasser F, Cherny N, Levan N. MASCC/ESMO/EAPC survey of palliative programs. Support Care Cancer. 2015;23:1951-68 pubmed publisher
    ..This study not only differs in some respects to a previous survey of palliative care programs but also confirms the late referral of patients to palliative care. ..
  8. Davis M, Strasser F, Cherny N. How well is palliative care integrated into cancer care? A MASCC, ESMO, and EAPC Project. Support Care Cancer. 2015;23:2677-85 pubmed publisher
    ..Financial concerns limit integration and expansion of palliative care services. Designated cancer centers have more extensive palliative care services relative to nondesignated cancer centers and urban hospitals. ..
  9. Davis M, Temel J, Balboni T, Glare P. A review of the trials which examine early integration of outpatient and home palliative care for patients with serious illnesses. Ann Palliat Med. 2015;4:99-121 pubmed publisher
    ..However, better designed and executed studies are needed to determine the best time to intervene and the best model of care. ..

More Information


  1. request reprint
    Davis M, Khawam E, Pozuelo L, Lagman R. Management of symptoms associated with advanced cancer: olanzapine and mirtazapine. A World Health Organization project. Expert Rev Anticancer Ther. 2002;2:365-76 pubmed
    ..The pharmacokinetics and pharmacodynamics of both agents are unique and explain many of the benefits. More research and clinical experience will be necessary to define their role in the palliation of advanced cancer. ..
  2. Davis M. New therapies for antiemetic prophylaxis for chemotherapy. J Community Support Oncol. 2016;14:11-20 pubmed publisher
    ..Compliance to guidelines in multiple settings ranges from 50%-60% but is improved by computerized order entry of antiemetics and recommendations displayed with chemotherapy. ..
  3. Davis M, Hallerberg G. A systematic review of the treatment of nausea and/or vomiting in cancer unrelated to chemotherapy or radiation. J Pain Symptom Manage. 2010;39:756-67 pubmed publisher
    ..Therefore, a systematic review based on the question "What is the evidence that supports antiemetic choices in advanced cancer?" guided this review...